Avacopan reduces need for glucocorticoids, respiratory and ENT involvement for vasculitis patients
Avacopan was better than prednisone in reducing respiratory as well as ear, nose and throat (ENT) involvement in ANCA-associated vasculitis patients participating in the phase 3 ADVOCATE trial, and enabled reduced glucocorticoid ...
May 18, 2022
0
9